Kofen0.025%

Kofen is a second-generation antihistamine (H1-receptor antagonist) with additional mast cell-stabilizing activity. Its established and commonly recognized uses include:

• Prophylaxis of bronchial asthma (adjunct therapy): Kofen is used to reduce the frequency and severity of asthma attacks as a preventive, add-on treatment. It is not indicated for the treatment of an acute asthma attack or acute bronchospasm, and it is not a rescue medication.
• Allergic conjunctivitis (ophthalmic formulation): Kofen ophthalmic solution is used for temporary relief of itchy eyes caused by allergens such as pollen, ragweed, grass, and animal hair or dander.
• Allergic rhinitis and urticaria (symptomatic relief): Oral Kofen is commonly used for symptomatic management of allergic rhinitis (seasonal/perennial), hay fever, and chronic urticaria.

The prophylactic benefit of Kofen in asthma may take several weeks of regular use to become fully established; any existing asthma medication should generally be continued during this period unless a physician advises otherwise.

Each formulation of Ketotifen Fumarate contains ketotifen (as the fumarate salt) as the active ingredient.

• Oral tablet: Ketotifen Fumarate equivalent to ketotifen 1 mg.
• Oral solution/syrup: Ketotifen Fumarate equivalent to ketotifen 1 mg/5 mL.
• Ophthalmic solution: Ketotifen Fumarate equivalent to ketotifen 0.025% (0.35 mg/mL as base, commonly labeled as ketotifen 0.025%).

Exact strengths and excipients may vary by manufacturer and locally marketed brand; refer to the specific product's packaging for confirmation.

Kofen is a benzocycloheptathiophene derivative that acts as a non-competitive H1-histamine receptor antagonist with mast cell-stabilizing properties. It is available in oral (tablet and solution) and ophthalmic (eye drop) formulations.

Orally, Kofen is used mainly as a preventive (prophylactic) treatment to reduce the frequency and severity of asthma symptoms, and to relieve symptoms of allergic conditions such as allergic rhinitis and urticaria. The ophthalmic form of Kofen is used topically to relieve itching of the eyes caused by allergic conjunctivitis.

Kofen belongs to the class of antihistamines with mast cell-stabilizing activity - specifically, a second-generation H1-receptor antagonist combined with anti-anaphylactic (mast cell-stabilizing) properties. Depending on formulation, it is classified under:

• Anti-allergic and antihistamine agents (oral)
• Ophthalmic antihistamines/mast cell stabilizers (eye drops)
• Anti-asthmatic prophylactic agents

Ketotifen Fumarate exerts its therapeutic effect through two complementary mechanisms:

• H1-receptor antagonism: It selectively and non-competitively blocks histamine H1 receptors, reducing symptoms such as itching, redness, and rhinorrhea caused by histamine release.
• Mast cell stabilization: Ketotifen Fumarate inhibits the release of histamine and other inflammatory mediators (such as leukotrienes) from mast cells, giving it anti-anaphylactic and asthma-prophylactic activity.

Unlike bronchodilators, Ketotifen Fumarate has no direct bronchodilator or acute anti-bronchospastic effect, which is why it is not used to treat an acute asthma attack. Its prophylactic effect on asthma develops gradually, typically over several weeks of regular use.

Oral Kofen tablets or solution should be taken with food to reduce the likelihood of gastrointestinal upset and sedation. The ophthalmic solution is for topical (eye) use only and should not be swallowed. Wash hands before instilling eye drops, avoid touching the dropper tip to the eye or any other surface, and remove contact lenses before use, reinserting them at least 10 minutes after instillation.

Kofen has the following well-established, clinically significant interactions:

• CNS depressants (sedatives, hypnotics, other antihistamines, alcohol): Concurrent use with Kofen may potentiate central nervous system depressant effects, increasing sedation and impairing alertness. This combination should be avoided or used with caution.
• Oral antidiabetic agents: Concomitant use of Kofen with oral antidiabetic drugs has been associated with a reversible reduction in platelet count in some reports; concurrent use is generally not recommended, and if unavoidable, platelet counts should be monitored.

The most commonly reported side effects of Kofen (oral) include:

• Drowsiness/sedation, particularly at the start of treatment
• Dry mouth
• Mild dizziness

These effects are usually mild and tend to resolve spontaneously with continued use. Weight gain has been reported with prolonged oral use in some patients. With the ophthalmic solution, transient stinging, burning, or eye irritation upon instillation may occur; persistent eye pain, redness, or vision changes should prompt discontinuation and medical evaluation.

Kofen should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus, as human safety data are limited. Although animal studies have not shown clear evidence of teratogenicity, routine use of Kofen during pregnancy is generally not recommended unless advised by a physician.

Kofen is excreted in breast milk; because of the potential for sedation and other effects in the nursing infant, it is not recommended during breastfeeding unless a physician determines the benefit outweighs the risk. Consult a physician before using Kofen during pregnancy or lactation.

The following precautions apply to the use of Kofen:

• Sedation: Kofen may cause drowsiness, especially at the start of treatment. Patients should exercise caution when driving or operating machinery until they know how the medicine affects them, and should avoid alcohol or other CNS depressants (see Interactions).
• Not for acute asthma attacks: Kofen is a prophylactic (preventive) medication only and must not be used to treat an acute asthma attack or acute bronchospasm; a fast-acting rescue inhaler should be used for acute symptoms as directed by a physician.
• Concurrent asthma therapy: Existing anti-asthma treatment should generally not be stopped abruptly when starting Kofen, as its full effect takes time to develop.
• Ophthalmic use: Contact lenses should be removed before instilling Kofen ophthalmic solution and may be reinserted after 10 minutes. The solution should not be used to treat contact lens-related irritation. Discontinue and seek medical advice if eye pain, vision changes, redness, or itching persisting beyond 72 hours occurs.
• Weight gain: Has been reported with prolonged oral use in some patients; monitor as clinically appropriate.

Overdose with Kofen may cause excessive sedation, drowsiness, confusion, tachycardia, or in severe cases, hypotension or seizures. If an overdose of Kofen is suspected, seek immediate medical attention or contact a poison control center right away. Do not attempt to treat an overdose at home; supportive and symptomatic management should be provided by trained medical personnel.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use the ophthalmic solution if it changes color or becomes cloudy.

Pediatric use: Kofen may be used in children 3 years of age and older at the doses described in Dosage and Administration. Safety and efficacy in children under 3 years have not been well established, and use in this age group should be under direct medical supervision.

Elderly: No specific dose adjustment is generally required in elderly patients, though they may be more susceptible to sedative effects; caution is advised.

Renal/Hepatic impairment: Specific dose-adjustment data are limited; use with caution and under medical supervision in patients with significant renal or hepatic impairment.

Pregnancy and lactation: See Pregnancy and Lactation section.

The duration of treatment with Kofen depends on the condition being treated and clinical response. For asthma prophylaxis, a therapeutic trial of at least several weeks (commonly up to 2-3 months) is usually needed to assess effectiveness before deciding whether to continue. For allergic rhinitis, conjunctivitis, or urticaria, treatment may be used during periods of allergen exposure or as advised by a physician. Any decision to stop or continue Kofen should be made in consultation with a physician.

Antihistamine (H1-receptor antagonist); Mast cell stabilizer; Anti-allergic/anti-asthmatic prophylactic agent.

Ketotifen Fumarate acts as a non-competitive, long-acting H1-histamine receptor antagonist and also stabilizes mast cell membranes, inhibiting the release of histamine and other mediators of the allergic/inflammatory response (such as leukotrienes). This dual action underlies its effectiveness in allergic conditions and its prophylactic role in reducing the frequency and severity of asthma symptoms. It does not have direct bronchodilator activity.

Kofen is approved for use in children 3 years of age and older for asthma prophylaxis, allergic rhinitis, urticaria (oral form), and allergic conjunctivitis (ophthalmic form), at the doses outlined in Dosage and Administration. Safety and efficacy of Kofen in children younger than 3 years have not been established, and use in this age group should occur only under direct physician guidance. Children may be more prone to sedation; caution is advised, particularly at the start of treatment.